Rhythm Pharmaceuticals, Inc. (RYTM) Q4 FY25 Earnings Call

Commercial growth is strong, but Bifamelegon’s Phase III requirements and sharply higher spending raise execution demands.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-02-27
Length58 minutes
EPS$-0.73
EPS consensus$-0.79
Revenue$51.3M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All RYTM earnings · Back to RYTM overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.